Patient
SITE010-0095
completed Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE010 (ESP) (Dr. Silva)
consented 2025-12-30
Adverse events
3
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 3
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-09-30 (study day 91); relationship: not assessed
Grade 4 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-03 (study day 64); relationship: NOT RELATED; serious criteria: life-threatening
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-07-19 (study day 18); relationship: not assessed
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.